Try a new search

Format these results:

Searched for:

in-biosketch:yes

person:morgag04

Total Results:

677


A novel functional role for MMSET in RNA processing based on the link between the REIIBP isoform and its interaction with the SMN complex

Mirabella, Fabio; Murison, Alexander; Aronson, Lauren I; Wardell, Christopher P; Thompson, Andrew J; Hanrahan, Sarah J; Fok, Jacqueline H L; Pawlyn, Charlotte; Kaiser, Martin F; Walker, Brian A; Davies, Faith E; Morgan, Gareth J
The chromosomal translocation t(4;14) deregulates MMSET (WHSC1/NSD2) expression and is a poor prognostic factor in multiple myeloma (MM). MMSET encodes two major protein isoforms. We have characterized the role of the shorter isoform (REIIBP) in myeloma cells and identified a clear and novel interaction of REIIBP with members of the SMN (survival of motor neuron) complex that directly affects the assembly of the spliceosomal ribonucleic particles. Using RNA-seq we show that REIIBP influences the RNA splicing pattern of the cell. This new discovery provides novel insights into the understanding of MM pathology, and potential new leads for therapeutic targeting.
PMCID:4055699
PMID: 24923560
ISSN: 1932-6203
CID: 3648432

Jumping translocations and high-risk myeloma [Comment]

Morgan, Gareth J
PMID: 24744247
ISSN: 1528-0020
CID: 3648392

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome

Brioli, Annamaria; Giles, Hannah; Pawlyn, Charlotte; Campbell, John P; Kaiser, Martin F; Melchor, Lorenzo; Jackson, Graham H; Gregory, Walter M; Owen, Roger G; Child, J Anthony; Davies, Faith E; Cavo, Michele; Drayson, Mark T; Morgan, Gareth J
Intraclonal heterogeneity was recently described in multiple myeloma (MM), but its full impact on disease progression and relapse has not been entirely explored. The immunoglobulin type produced by myeloma cells provides an excellent marker to follow changes in clonal substructure over time. We have prospectively evaluated serial paraprotein and serum free light chain (FLC) measurements and found that 258 of 520 and 54 of 520 patients who presented with a whole paraprotein relapsed with paraprotein only (PO) and "FLC escape," respectively. The median overall survival of PO patients was longer, when compared with patients whose relapse manifested as an increase in FLC both alone and with a whole paraprotein, as a result of a significantly shorter survival from relapse of the latter groups. These observations fit a model in which 1 clone is able to produce a complete antibody, whereas the other secretes only FLC; the type of relapse represents the outgrowth of different clones, some of which are more resistant to therapy. To our knowledge, this is the largest series describing patients who have relapsed with FLC escape and highlights the importance of monitoring FLC when there is a suspicion of clinical relapse. This study was registered at www.isrctn.org as ISRCTN68454111.
PMID: 24733348
ISSN: 1528-0020
CID: 3648382

Understanding the multiple biological aspects leading to myeloma [Editorial]

Boyle, Eileen M; Davies, Faith E; Leleu, Xavier; Morgan, Gareth J
PMCID:3971069
PMID: 24688108
ISSN: 1592-8721
CID: 3648372

Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results

Jackson, Graham H; Morgan, Gareth J; Davies, Faith E; Wu, Ping; Gregory, Walter M; Bell, Sue E; Szubert, Alexander J; Navarro Coy, Nuria; Drayson, Mark T; Owen, Roger G; Feyler, Sylvia; Ashcroft, Andrew J; Ross, Fiona M; Byrne, Jennifer; Roddie, Huw; Rudin, Claudius; Boyd, Kevin D; Osborne, Wendy L; Cook, Gordon; Child, J Anthony
Bisphosphonates are recommended in patients with osteolytic lesions secondary to multiple myeloma. We report on the safety of bisphosphonate therapy with long-term follow-up in the Medical Research Council Myeloma IX study. Patients with newly diagnosed multiple myeloma were randomised to zoledronic acid (ZOL; 4 mg intravenously every 21-28 d) or clodronate (CLO; 1600 mg/d orally) plus chemotherapy. Among 1960 patients (5.9-year median follow-up), both bisphosphonates were well tolerated. Acute renal failure events were similar between groups (ZOL 5.2% vs. CLO 5.8% at 2 years; incidence plateaued thereafter). The overall incidence of confirmed osteonecrosis of the jaw (ONJ) was low, but higher with ZOL (ZOL 3.7% vs. CLO 0.5%; P < 0.0001). ONJ events were generally low grade and most occurred between 8 and 30 months (median time to ONJ, 23.7 months). Among 10 patients with ONJ recovery data, four patients in the ZOL group completely recovered, two patients improved, and three patients experienced no improvement; one CLO patient experienced no improvement. Dental surgery or trauma preceded ONJ in six ZOL patients. The incidence of renal adverse events was similar for ZOL and CLO. ONJ incidence remained low and was lower with CLO compared to ZOL. We have seen no further ONJ cases to date.
PMID: 24673708
ISSN: 1365-2141
CID: 3648362

Inherited genetic susceptibility to monoclonal gammopathy of unknown significance

Weinhold, Niels; Johnson, David C; Rawstron, Andrew C; Försti, Asta; Doughty, Chi; Vijayakrishnan, Jayaram; Broderick, Peter; Dahir, Nasrin B; Begum, Dil B; Hosking, Fay J; Yong, Kwee; Walker, Brian A; Hoffmann, Per; Mühleisen, Thomas W; Langer, Christian; Dörner, Elisabeth; Jöckel, Karl-Heinz; Eisele, Lewin; Nöthen, Markus M; Hose, Dirk; Davies, Faith E; Goldschmidt, Hartmut; Morgan, Gareth J; Hemminki, Kari; Houlston, Richard S
Monoclonal gammopathy of undetermined significance (MGUS) is present in ∼2% of individuals age >50 years. The increased risk of multiple myeloma (MM) in relatives of individuals with MGUS is consistent with MGUS being a marker of inherited genetic susceptibility to MM. Common single-nucleotide polymorphisms (SNPs) at 2p23.3 (rs6746082), 3p22.1 (rs1052501), 3q26.2 (rs10936599), 6p21.33 (rs2285803), 7p15.3 (rs4487645), 17p11.2 (rs4273077), and 22q13.1 (rs877529) have recently been shown to influence MM risk. To examine the impact of these 7 SNPs on MGUS, we analyzed two case-control series totaling 492 cases and 7306 controls. Each SNP independently influenced MGUS risk with statistically significant associations (P < .02) for rs1052501, rs2285803, rs4487645, and rs4273077. SNP associations were independent, with risk increasing with a larger number of risk alleles carried (per allele odds ratio, 1.18; P < 10(-7)). Collectively these data are consistent with a polygenic model of disease susceptibility to MGUS.
PMID: 24449210
ISSN: 1528-0020
CID: 3648322

Reply to M. Roschewski et al [Comment]

Rawstron, Andy C; Child, J Anthony; de Tute, Ruth M; Davies, Faith E; Gregory, Walter M; Bell, Sue E; Szubert, Alexander J; Navarro Coy, Nuria; Drayson, Mark T; Feyler, Sylvia; Ross, Fiona M; Cook, Gordon; Jackson, Graham H; Morgan, Gareth J; Owen, Roger G
PMID: 24419132
ISSN: 1527-7755
CID: 3648302

The impact of long-term lenalidomide exposure on the cellular composition of bone marrow [Letter]

Brioli, Annamaria; Melchor, Lorenzo; Titley, Ian; Vijayaraghavan, Gowri; Stephens, Claire; Zeisig, Athanasia; Pawlyn, Charlotte; Cavo, Michele; Morilla, Ricardo; Davies, Faith E; Morgan, Gareth J
PMID: 24660850
ISSN: 1029-2403
CID: 3648352

Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma

Giles, Sharon L; Messiou, Christina; Collins, David J; Morgan, Veronica A; Simpkin, Catherine J; West, Sharon; Davies, Faith E; Morgan, Gareth J; deSouza, Nandita M
PURPOSE/OBJECTIVE:To determine the feasibility of whole-body diffusion-weighted (DW) magnetic resonance (MR) imaging for assessment of treatment response in myeloma. MATERIALS AND METHODS/METHODS:This prospective single-institution study was HIPAA-compliant with local research ethics committee approval. Written informed consent was obtained from each subject. Eight healthy volunteers (cohort 1a) and seven myeloma patients (cohort 1b) were imaged twice to assess repeatability of quantitative apparent diffusion coefficient (ADC) estimates. Thirty-four additional myeloma patients (cohort 2) underwent whole-body DW imaging before treatment; 26 completed a posttreatment imaging. Whole-body DW data were compared before and after treatment by using qualitative (ie, observer scores) and quantitative (ie, whole-body segmentation of marrow ADC) methods. Serum paraproteins and/or light chains or bone marrow biopsy defined response. RESULTS:Whole-body DW imaging scores were significantly different between observers (P < .001), but change in scores between observers after treatment was not (P = .49). Sensitivity and specificity for detecting response according to observer scores were 86% (18 of 21 patients) and 80% (4 of 5 patients) for both observers. ADC measurement was repeatable: mean coefficient of variation was 3.8% in healthy volunteers and 2.8% in myeloma patients. Pretreatment ADC in cohort 2 was significantly different from that in cohort 1a (P = .03), but not from that in cohort 1b (P = .2). Mean ADC increased in 95% (19 of 20) of responding patients and decreased in all (five of five) nonresponders (P = .002). A 3.3% increase in ADC helped identify response with 90% sensitivity and 100% specificity; an 8% increase (greater than repeatability of cohort 1b) resulted in 70% sensitivity and 100% specificity. There was a significant negative correlation between change in ADC and change in laboratory markers of response (r = -0.614; P = .001). CONCLUSION/CONCLUSIONS:Preliminary work demonstrates whole-body DW imaging is a repeatable, quantifiable technique for assessment of treatment response in myeloma.
PMID: 24475858
ISSN: 1527-1315
CID: 3648332

The impact of intra-clonal heterogeneity on the treatment of multiple myeloma

Brioli, Annamaria; Melchor, Lorenzo; Cavo, Michele; Morgan, Gareth J
It is clear that cancers comprise a mixture of clones, a feature termed intra-clonal heterogeneity, that compete for spatial and nutritional resources in a fashion that leads to disease progression and therapy resistance. This process of competition resembles the schema proposed by Darwin to explain the origin of the species, and applying these evolutionary biology concepts to cancer has the potential to improve our treatment strategies. Multiple myeloma (MM) has a unique set of characteristics that makes it a perfect model in which to study the presence of intra-clonal heterogeneity and its impact on therapy. Novel therapies have improved the outcome of MM patients, increasing both progression-free and overall survival. Current therapy comprises an induction, consolidation and maintenance phases and it is important to consider how these components of MM therapy are affected by the presence of intra-clonal heterogeneity. In this evolutionary context therapy can be considered as a selective pressure differentially acting on the myeloma clones and impacting on their chances of survival. In this review current knowledge of intra-clonal heterogeneity, as well as its impact on the different components of MM treatment is discussed.
PMID: 24580032
ISSN: 1365-2141
CID: 3648342